Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Jul 21, 2009

Researchers Find Two Genes that Promote Chemoresistance in Liver Cancer Cells

  • Two genes may contribute to resistance to 5-fluorouracil (5-FU) chemotherapy in liver cancer patients, according to Virginia Commonwealth University (VCU) Massey Cancer Center researchers. The genes are called astrocyte elevated gene-1 (AEG-1) and late SV40 factor (LSF), as reported in a study published online in the July 13 early edition of the Proceedings of the National Academy of Sciences.

    The team found that overexpression of AEG-1 increased resistance of the liver to 5-FU. They also observed that LSF is under the control of AEG-1 and mediates a series of molecular pathways involved with 5-FU resistance. 

    Previous studies found that the expression of AEG-1 was very low in normal cells or tissues such as breast, prostate, liver, and brain. In cancers of the same organs, however, AEG-1 expression was significantly increased. 

    The VCU team determined that AEG-1 modulates expression of genes relevant to the progression of liver cancer, including invasion, metastasis, resistance to chemotherapy, the formation of new blood vessels, and senescence. They identified that LSF, a transcription factor that regulates gene expression, is increased by AEG-1.

    The researchers say that AEG-1 contributes to resistance to not only 5-FU but also to other chemotherapeutics such as doxorubicin and cisplatin, although the molecular mechanism of resistance to the latter drugs is different from 5-FU.

    The team is currently conducting studies to further understand the molecular mechanisms by which AEG-1 induces resistance to chemotherapy. Additionally, novel combinatorial treatment approaches that incorporate AEG-1 or LSF inhibition in a standard chemotherapeutic protocol will be evaluated for their efficacy in inhibiting liver cancer in animal models.



Related content

Be sure to take the GEN Poll

Drug Price Hikes

Novum Pharma recently raised the price of an acne cream by over 3,900% in less than a year-and-a-half and Mylan increased price of EpiPen from $100 to $608 . Do you think pharmaceutical companies need to be subjected to price controls?

More »